Skip to main content

COVID-19 Funding Opportunities

Below is a list of research-funding databases, portals and opportunities specifically related to COVID-19. Not all of these opportunities are necessarily an ideal match for Eberly College faculty specifically, but this is intended as a wide-ranging resource for the university community as a whole. Please keep checking back as we will update this list frequently!

Index
Funding Portals and Search Engines
West Virginia Resources
Federal Opportunities
Private Foundations, Corporations and Other Agencies
Additional Resources and Databases

Funding Portals and Search Engines

Pivot at West Virginia University
Pivot focuses on what matters most to you—the ability to identify and connect with funding opportunities and other researchers, locally and globally. It combines the most comprehensive, editorially-maintained database of funding opportunities worth an estimated $33 billion with a unique database of 3 million scholar profiles—and growing. Access to Pivot is limited to authenticated users only; you must have an email address that ends in one of the following ways:  mail.wvu.edu, mix.wvu.edu, or hsc.wvu.edu. To stay updated on COVID-19 funding information, we recommend saving a “COVID-19” search. Results will be emailed to you weekly.
https://pivot.proquest.com

Grant Station
Current funding opportunities for nonprofits in the area of COVID-19, updated each business day and listed by deadline date. Use Ctrl + F on your keyboard to search funding opportunities or jump to a particular section of interest by using the links directly:
https://grantstation.com/covid19fundingsopps

Johns Hopkins University COVID-19 Funding Opportunities
The JHU Office of the Vice Provost for Research (VPR) has compiled several funding opportunities specific to COVID-19. This list will be updated as new opportunities arise.
https://hub.jhu.edu/novel-coronavirus-information/research-preparedness/research-preparedness-covid-19-funding-opportunities/

InfoEd Global COVID-19/Coronavirus Resources
InfoEd Global is proud to be able to share this library of COVID-19 funding opportunities and resources with our colleagues in the research realm and the broader community at large.
https://www.infoedglobal.com/COVID19/COVID-19

COSSA Compiling Social Science Resources Related to COVID-19
COSSA (Consortium of Social Science Associations) is compiling a list of resources for social scientists and stakeholders related to the COVID-19 pandemic. The list includes guidance from federal science agencies, collections of publicly available peer-reviewed research related to the crisis, resources from COSSA member associations, and more. There are a number of new databases for researchers wishing to amplify their work that may have relevance to the current crisis, including the COVID-19 Open Research Dataset, supported by the Allen Institute for AI, and a grassroots effort on GitHub to compile new social science research related to COVID-19.
https://www.cossa.org/resources/covid-19/

USDA COVID-19 Federal Rural Resource Guide

The COVID-19 Federal Rural Resource Guide is a helpful resource published by the U.S. Department of Agriculture unveiled by the USDA for rural communities looking for federal funding and partnership opportunities to help address COVID-19. This resource matrix organizes funding opportunities identified in the CARES Act and other federal resources that can help support rural America. Opportunities are categorized by customer and assistance type.
https://www.rd.usda.gov/sites/default/files/USDA_COVID-19_Fed_Rural_Resource_Guide.pdf 

West Virginia Resources

West Virginia COVID-19 Information Portal
This resources includes state grants, available funding sources, links to federal grants and grant application guidelines. 
https://grants.wv.gov/en  

COVID-19 Business Relief Resources
In order to aid businesses and communities dealing with the impact of COVID-19, the West Virginia Department of Commerce has developed a directory of human and financial resources. Please continue to receive public health information from the Department of Health and Human Resources and Governor Jim Justice’s official website. Below you will find important information about resources from both state and federal agencies available to businesses and communities affected economically from COVID-19.
https://westvirginia.gov/covid19/

Philanthropy West Virginia COVID-19 Relief Funds
Philanthropy West Virginia has created a list of emergency relief funds from West Virginia’s Community Foundations, United Way agencies and other local organizations. These organizations are accepting donations, and providing relief to West Virginia nonprofit organizations communities affected by the pandemic.
http://www.philanthropywv.org/covid-19-relief-funds/

YCF Emergency Impact Grants in Response to COVID-19  
In response to the ongoing COVID-19 pandemic, our Board of Directors has established the YCF Emergency Impact Fund. Targeted to assist nonprofit organizations in the five-county region served by YCF (Harrison, Marion, Monongalia, Preston, and Taylor Counties), the new fund will provide grant funding to nonprofits addressing the most critical needs in our communities. Grants must be used for unanticipated, additional expenses related to COVID-19.  Currently, we invite those organizations providing human services to apply. Awards of up to $2,500 will be made on a rolling basis. Funding priorities are emergency food, shelter, and other basic needs for the most vulnerable members of our community.
http://www.ycfwv.org/grant-opportunities/
Applications accepted on a rolling basis. 

Federal Opportunities

Index
National Institute of Health
National Science Foundation
Other Federal Opportunities 

NATIONAL INSTITUTE OF HEALTH 

NIH Funding Opportunities Specific to COVID-19
This new page contains a listing of active and expired funding opportunities specific to Coronavirus Disease 2019 (COVID-19).
https://grants.nih.gov/grants/guide/COVID-Related.cfm

Funding for NEW NIH-funded Projects

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.
https://grants.nih.gov/grants/guide/pa-files/PAR-20-243.html
Deadline(s): December 2, 2020, March 2, 2021

Notice of Special Interest (NOSI) - Research on Rehabilitation Needs Associated with the COVID-19 Pandemic
The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of survivors of COVID-19; Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions; Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities; and Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the National Center for Medical Rehabilitation Research (NCMRR) at NICHD. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice: PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed); PA-18-480- NICHD Research Project Grant (Parent R01 Clinical Trial Required); PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed); PA-20-194- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-031.html
Deadline: February 5, 2021

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
NIEHS seeks to promote rapid understanding of the potential contributions of current and past exposure to environmental agents that may exacerbate COVID-19 susceptibility, disease severity, and progression. Examples of environmental exposures relevant to the NIEHS mission include: toxic chemicals, air pollutants, second hand tobacco smoke, e-cigarette vapors, metals, and other environmental chemical exposures that may impact health outcomes. In addition, some health outcomes that are linked to environmental exposures (asthma, diabetes, and other pulmonary, cardiovascular, and metabolic diseases) are also risk factors for COVID-19. NIEHS is accepting applications addressing COVID-19 through the administrative supplement, urgent competitive revision, and time-sensitive mechanisms.
https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-020.html
Deadline: May 4, 2021

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project
NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus. Applications for this initiative must be submitted electronically using one of the following target opportunities or their subsequent reissued equivalents: PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) or PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)
https://grants.nih.gov/grants/guide/notice-files/not-od-20-129.html
Deadlines: March 12, 2021 and July 12, 2021

NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19).
https://grants.nih.gov/grants/guide/pa-files/PAR-20-234.html
Deadline(s): January 4, 2021 and February 1, 2021

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)      
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). 
https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html  
Deadline: Applications will be accepted on a rolling basis

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)      
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).  
https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html
Deadline: Applications will be accepted on a rolling basis

NIH Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)  
NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. NIAID is therefore encouraging applications to address research objectives described in the link below. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-20-135; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.  
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html  
Deadline: Rolling , through April 5, 2021

NIH Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)
NIEHS considers the COVID-19 pandemic to be an unpredictable event that provides a limited window of opportunity to collect human biological samples or environmental exposure data (e.g measuring levels of pollutants in air or water during a long period of social distancing due to COVID-19). If you are applying for a new R21 grant that does not build off of an existing NIEHS grant, the NIEHS recommends applying through this funding opportunity announcement (FOA) that is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.
https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-011.html
Deadline(s): Applications are accepted on a rolling basis through October 3, 2022

NIH Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.
https://grants.nih.gov/grants/guide/PA-files/PA-20-172.html
Deadline:  Standard dates apply

AHRQ Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19   
AHRQ intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare professional response to COVID-19. Grant activity codes to be included or excluded from the funding notice will specified in the announcement. It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. Competitive revision supplements will be limited in duration (perhaps 12 months). The amount of supplemental funds that may be requested will be limited, and will be specified in the funding notice. AHRQ expects to make at least $2.5M available to fund meritorious revision supplements in FY2020. AHRQ plans to release the supplement announcement in April 2020 with an opening date in mid-May. Please also see AHRQ’s Notice of Intent to publish a new FOA requesting new competitive applications targeting the evaluation of health system responsiveness to COVID-19.   
https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-007.html   
Deadline: TBD

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.
https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html
Deadline: Applications will be accepted on a rolling basis through January 24, 2021

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities
The NIH has released a Notice of Special Interest to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities, including those related to COVID-19. Proposals should be submitted using the funding opportunity announcement “PA-20-185 – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).” The specific areas of interest of each participating institute or center are listed in the NOSI (see link), but in general, proposals are solicited for projects addressing the following research objectives:

  • Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using simulation modeling and systems science (SMSS)
  • Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities
  • Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities
  • Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities
  • Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings
  • Promote big data harmonization and novel analytic methods in SMSS to address minority health and health disparities
https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-025.html
Deadline:  Standard R01 Deadlines  from October 5, 2020 through May 8, 2023 apply

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
The National Institute of Allergy and Infectious Diseases has issued a Notice of Special Interest encouraging cooperative agreement applications for the implementation of investigator-initiated, high-risk clinical trials, as defined by NIAID in  PAR-18-633 and  NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2. Proposals should be submitted using the funding opportunity announcement “PAR-18-633 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).” Proposals are sought to evaluate SARS-CoV-2 candidate vaccines, non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19, and therapeutic approaches to treat COVID-19. Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative.
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-065.html
Deadline: Once a month, from September 14, 2020 through September 14, 2021

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate: SARS-CoV-2 candidate vaccines, non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19, and therapeutic approaches to treat COVID-19. Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative. Submit applications for this NOSI initiative to the following funding opportunity announcements (FOAs) or any reissues of this announcement through the expiration date of this notice: PAR-18-633 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-065.html
Deadline: Applications will be accepted on the 14th of each month, from September 14, 2020 through September 14, 2021

NICHD Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract
The NICHD invites applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. This NOSI is interested in the recently emergent ZIKA and novel corona viruses, as well as other yet unidentified viruses which may significantly impact public health. Proposals should be submitted to either PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) or PA-18-482 NICHD Exploratory/Developmental Research Grant (R21 – Clinical Trial Optional).
https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-021.html
Deadline: Standard R01 due dates apply through May 8, 2023.

Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects
NIAID is issuing this Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains. To advance pan-CoV vaccine development, this program will support research to design and develop vaccine approaches intended to provide durable immunity against CoVs with an emphasis on CoVs with pandemic potential. Programs should be composed of research projects that: Address CoV diversity and infectious potential in humans as it relates to vaccine design challenges; Include innovative immunogen design and vaccine platforms/approaches to elicit potent and durable pan-CoV immunity; Evaluate CoV vaccine candidates in preclinical models, incorporating detailed immunologic assessments in blood and tissues.
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-002.html
Applications Deadlines: January 11, 2021 and June 11, 2021.

Administrative Supplements and Competitive Revisions for EXISTING NIH-Funded Projects

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals withDown syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.
Applications for this initiative must be submitted electronically using one of the following target opportunities or their subsequent reissued equivalents:

  • PA-18-591   Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
  • PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-129.html
Deadlines: March 12, 2021 and July 12, 2021

Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
Coronavirus Disease 2019 (COVID-19) is a recently emerged human disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models. See the guidelines for a list funding opportunity announcements (FOAs) that may be used to submit applications under this NOSI.
Deadline: This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022 

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System   
NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. In order to rapidly improve our understanding of the neurological consequences of infection of SARS-CoV-2 and of COVID-19, NINDS is encouraging the submission of applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus that are directly related to the NINDS mission. Applications for this initiative must be submitted using one of the following opportunity announcements or the subsequent reissued equivalent.  PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) or  PA-18-935 - Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional). Applications for research that fall within the scope of an existing NINDS award should be submitted through  PA-18-591 (Parent Admin Supp Clinical Trial Optional). Eligible activity codes fare limited to the mechanisms listed in  PA-18-591
https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-051.html
Deadline: Applications will be accepted on a rolling basis until April 14, 2021

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)  
Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus, 2019-nCoV, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, China. Current information regarding confirmed cases is changing daily and can be found on the  Centers for Disease Control and Prevention website and through other sources such as the  NIH website. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of viral pathogenesis, natural history, and host range are poorly understood. Given this, there is an urgent public health need to better understand the 2019-nCoV, particularly to improve prevention of disease transmission among older adults and mitigation of disease severity and mortality in older adults with COVID-19. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements ( PA-18-591) or Competitive Revisions ( PA-18-935) to active grants to address the research areas outlined on the site below.  Participating Institutes include NIA, NIMH, and NIAAA.  
https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html 
Deadline: Applications will be accepted on a  rolling basis through May 1, 2021  

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus  
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.A multi-organ on chip approach is strongly encouraged though not required. Please document access to a BSL-3 facility or include scientific justification for use of alternative facilities, for example using an engineered a COVID-19 pseudovirus that expresses the key surface Spike protein, which mediates its entry into cells. This Notice announces the availability of administrative supplements for investigators and institutions funded through: The NIH Microphysiological Systems (MPS) Program; or SBIR/STTR-supported investigators, provided the award involves tissue chips; or Microphysiological systems programs from across NIH. Applications for this initiative must be submitted using  PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) 
https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html
Deadline: Applications will be accepted on a rolling basis through January 25, 2022   

NIH Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus 
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications in response to this NOSI must be submitted using the targeted funding opportunities in the link below. 
https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html 
Deadline: Rolling through March 31, 2021

NIH Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)  
NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. NIAID is therefore offering Competitive Revisions to active NIAID grants addressing research objectives at the link below. 
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html 
Deadline: Rolling, through March 25, 2021  

Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA  
The impact of the COVID-19 pandemic on the nation is vast, especially on health and well-being. Research suggests that alcohol consumption tends to increase during times of duress and uncertainty such as disasters and other traumatic events, and as such alcohol is often misused to cope with stress, anxiety, and other uncomfortable emotions. In addition, the misuse of alcohol to cope with the stress as a result of physical distancing and other policy measures, and a lack of access to supportive social networks and treatment for people with pre-existing alcohol use disorder (AUD) are significant concerns during the pandemic. These outcomes are particularly challenging with respect to COVID-19 because alcohol misuse can interfere with normal immune system function and elevate susceptibility to viral infections of the respiratory system. Alcohol-associated damage to the liver, heart, and other organs may also complicate health outcomes in individuals with COVID-19. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes. NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent. PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)  PA-18-935 - Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
Deadline: Applications will be accepted on a rolling basis through April 15, 2021

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)
NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS seeks to promote rapid understanding of the potential contributions of current and past exposure to environmental agents that may exacerbate COVID-19 susceptibility, disease severity, and progression. Examples of environmental exposures relevant to the NIEHS mission include: toxic chemicals, air pollutants, second hand tobacco smoke, e-cigarette vapors, metals, and other environmental chemical exposures that may impact health outcomes. In addition, some health outcomes that are linked to environmental exposures (asthma, diabetes, and other pulmonary, cardiovascular, and metabolic diseases) are also risk factors for COVID-19. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms. To better understand the role of environmental exposures in SARS-Cov-2 transmission and COVID-19 disease incidence and progression, NIEHS encourages applications to be submitted using the following opportunities: 
  • PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
Deadlines: January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus  
NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Applications in response to this NOSI must be submitted using the following targeted funding opportunities or their subsequent reissued equivalents:PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant. PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant. 
https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html 
Deadline: Rolling, through April 15, 2021

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences  
This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health. Applications in response to this NOSI must be submitted using the following targeted funding opportunities or subsequent re-issued equivalents:  PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to  expand the scope of their active grant.  PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant. Participating institutes and centers include the OBSSR, NHLBI, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, NICHD, and NINR.  
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html 
Deadline: Rolling, through March 31, 2021

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities  
This NOSI is soliciting research in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations. Outcomes of interest include, but are not limited to, the COVID-19 incidence, prevalence, and mortality rates in defined populations; substance abuse and mental health effects; impact on chronic conditions; effects on severe maternal morbidity and mortality; and influence on access, utilization, and quality of health care (including needed medical care, medical treatments, and access to prescription drugs) Projects must include a focus on one or more NIH-designated populations that experience health disparities in the United States, which include racial and ethnic minority groups (Blacks or African Americans, Hispanics or Latinos, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders), less privileged socioeconomic status, sexual and gender minorities and underserved rural populations. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequent reissued equivalent.  PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is within the scope of the ongoing grant.  PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant.  Participating Institutes include NIMHD, NIA and NIMH. 
https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html 
Deadline: Rolling, through May 1, 2021

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces NOT-AI-20-034 which was rescinded with this issuance of this Notice. NIAID is allowing the submission of applications for Competitive Revisions to active grants to increase and enhance select research efforts to facilitate the Federal SARS-CoV-2/COVID-19 research response. Areas of interest are limited to: Support to BSL3 facilities actively engaged in the SARS-CoV-2/COVID-19 research response, e.g., equipment sharing arrangements. Applications proposing new construction, alterations and renovations for planned and active BSL3 facilities are not responsive to this NOSI; Generation of critical reagents to support the SARS-CoV-2/COVID-19 research response; Expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad research community; and Expansion of clinical trial infrastructure, or site preparation, for urgent SARS-CoV-2/COVID-19 clinical trial activities. Applications proposing clinical trials are not responsive to this NOSI. Investigators interested in responding to this NOSI are strongly encouraged to contact the program officers listed below to discuss the proposed project in the context of the parent award and the limited and specific NIAID needs identified above.
Applications in response to this NOSI must be submitted using the following targeted funding opportunity or subsequently reissued equivalent: PA-20-135; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html
Deadline: July 2, 2021

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest: Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants); Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only); Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only). Applications that are not responsive to the above research areas of interest will be withdrawn without review.
https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html
Deadline:  Applications will be accepted on a rolling basis through February 5, 2021

NOSI Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases

The outbreak of COVID-19 caused by the novel SARS-CoV-2 has spread worldwide leading to large numbers of infections and deaths. A wide spectrum of clinical manifestations and outcomes, ranging from asymptomatic disease to multiorgan failure, has become a hallmark of the COVID-19 pandemic. Patients with many underlying diseases and conditions are at increased risk of acquiring and having adverse outcomes from SARS-CoV-2 infection. Furthermore, persistent symptoms (post-acute sequelae), including fatigue, muscle pain, weakness or wasting, joint pain, skin rash, arthritis, and biobehavioral changes, are being reported among COVID-19 survivors, even among individuals who initially experience a mild acute illness. As of this writing, the FDA has issued Emergency Use Authorization for two vaccines recommended to prevent COVID-19, and several other vaccines and treatments are in various stages of preclinical and clinical development. While there is no obvious indication of adverse events or impacts of the use of these vaccines in individuals with underlying rheumatic, skin, and or musculoskeletal diseases/conditions, research studies should be carried out to determine if these individuals will be affected differently by COVID-19 vaccines and treatments as compared to those without such conditions. In line with overall NIH efforts, NIAMS would like to promote basic, translational, pre-clinical and clinical observational research focused on COVID-19 infection and its intersection with rheumatic, musculoskeletal, and skin diseases and conditions. This notice applies to due dates on or after February 5, 2021 and subsequent receipt dates through November 18, 2021.  Applications should be submitted for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice. 

  • PA-20-185: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-20-195: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) 
  • PAR-21-055: Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) 
  • PAR-21-054: Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) 
  • PAR-21-053: Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
Deadline: Standard Dates apply.

NATIONAL SCIENCE FOUNDATION

NSF Dear Colleague Letter on the Coronavirus  
The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge. 
https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp?org=NSF 
Deadline: rolling

NSF Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)  
The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. 
https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp?WT.mc_id=USNSF_80 
Deadline: rolling

NSF Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19 
NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I Program. 
https://www.nsf.gov/pubs/2020/nsf20065/nsf20065.jsp 
Deadline: rolling 

OTHER FEDERAL OPPORTUNITIES

Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing   
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. NIBIB  is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to  clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution.  
https://www.poctrn.org/radx  
Deadline: rolling

Innovative Commercial Products in Support of Coronavirus (COVID-19) Response Commercial Solutions Opening Pilot Program (CSOP)
The Department of Homeland Security (DHS) efforts in preparedness and readiness have facilitated a speedy, whole-of-government response in confronting COVID-19, keeping Americans safe, and helping detect and slow the spread of the virus. DHS is seeking innovative commercial products that are in support of the COVID-19 response or similar microbial threats. Considering the magnitude and potential threat that COVID-19 and similar microbial threats pose to our nation’s health, safety and security, the Government seeks to rapidly accelerate the testing and fielding of new capabilities, employing innovative commercial products to the detection of exposure, prevention, containment and treatment of COVID-19 and similar microbial threats. Such innovative commercial products would be in support of the mission of the DHS, including the assistance that the FEMA is providing, in coordination with the HHS, to state, local, tribal, territorial governments and other eligible entities under the Stafford Act.
Deadline: rolling  

NIST Manufacturing USA National Emergency Assistance Program  
NIST invites applications from the 2,000 current Manufacturing USA institutes, including small manufacturers, two-thirds of Fortune 50 U.S. manufacturers, and nearly every top ranked research and engineering university in the United States. NIST invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic. 
https://www.grants.gov/web/grants/search-grants.html?keywords=2020-NIST-MFGUSA-NEAP-01 
Deadline: rolling, through March 31, 2021   

Biomedical Advanced Research and Development Authority (BARDA)  
BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat. BARDA, with a total budget of $512 Million, is seeking proposals through the following mechanisms:

Deadline: rolling 

Corona Watch 
The U.S. government is providing a portal for the 2019 novel coronavirus (COVID-19) medical countermeasures task force as a single point of entry for the submission of market research packages and meeting requests from interested stakeholders. The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development.  Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed. Ideal technologies and products would (but are not required to) be: Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities; Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability; Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate) 
https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/ 
Deadline: rolling

White House Announces the Launch of the COVID-19 High-Performance Computing Consortium
The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. The consortium hopes to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections.
https://www.xsede.org/covid19-hpc-consortium
Deadline: rolling

COVID-19 Private Sector Engagement & Partnership Fund
The U.S. Department of State, Office of Global Partnerships (E/GP) welcomes concept paper submissions for the FY 2020 Fund for partnerships supporting COVID-19 relief efforts around the world. The Fund will leverage private sector contributions, technology and innovations, and pivot The Department of State's approach to how we provide technical assistance to scale up readiness and response operations in emerging markets and developing countries. The Department is specifically looking for concept papers that will enable people around the world to mitigate the COVID-19 virus's effects on their societies. Concepts that work to enable an economic response to the virus, such as local production of ventilators, personal protective equipment, virtual education and other economic engagement is welcome. These examples are only made for illustrative purpose and the Department welcomes hearing of the creativity from the private sector.
https://www.grants.gov/web/grants/view-opportunity.html?oppId=328509
Deadline: May 28, 2021

DOS Office to Monitor and Combat Trafficking in Persons (TIP) Annual Program Statement to Address the Impacts of COVID-19
This annual program statement announces the beginning of an open, one-stage competitive process to award grants and cooperative agreements to address the impacts of COVID-19 on effort to combat human trafficking and support government measures to counter human trafficking. The TIP Office recognizes the pressures governments and civil society organizations are under to combat human trafficking and manage the impacts of COVID-19. As such, the TIP Office encourages applicants to propose innovative concepts to address the impacts of COVID-19 on efforts to combat human trafficking and support government measures to counter human trafficking. Applications are encouraged to note recommendations in the TIP Report and link proposed activities to the recommendations as best as possible.
https://www.grants.gov/web/grants/view-opportunity.html?oppId=328674
Deadline: June 31, 2021

Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) Commercial Solutions Opening
The DAF ACT Commercial Solutions Opening (CSO) is a contract opportunity that seeks innovative, commercial technologies that propose new solutions and/or potentially new capabilities that fulfill requirements, close capability gaps, or provide potential technological advancements in support of the COVID-19 Response Acquisition Task Force mission to provide relief, resilience, recovery, and stability to the nation in response to the COVID-19 pandemic. This CSO may have areas of interest (AoIs) that result in an award of prototype projects, which include not only commercially available technologies fueled by commercial or strategic investment but also concept demonstrations, pilots, and agile development activities that can incrementally improve commercial technologies, existing government-owned capabilities, and/or concepts for broad defense and/or public application(s). Solution Briefs will be solicited by the posting of DAF ACT AoIs within predetermined Mission Focus Areas that identify generalized areas of need.
https://beta.sam.gov/opp/89af9e98d83e4650aab9bcd250bd00c4/view
Deadline: Varies by AOI

CDC Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services to Mitigate Morbidity and Mortality
The purpose of this notice of funding opportunity is to understand the needs of emergency-affected and displaced populations by improving epidemiological methods, estimating morbidity and mortality of these populations during COVID-19, as well as understand the specific health sector needs of persons affected by humanitarian /public health emergencies and best practices for improving health outcomes.
https://www.grants.gov/web/grants/view-opportunity.html?oppId=329756
Deadline: February 18, 2021

Strengthening Public Health Research and Implementation Science (Operations Research) to Control and Eliminate Infectious Diseases Globally
The purpose of this Notice of Funding Opportunity (NOFO) is to support the following activities:

  • Conduct and monitor epidemiologic and laboratory-based science, surveillance, and research related to COVID-19 and other global public health threats in Africa, Southeast Asia, Eastern Europe and Central Asia, and the Middle East and North Africa (MENA), including, but not limited to, assessments of the extent of pathogen exposures or transmission based on serologic testing, improved understanding of immune responses to infectious pathogens, and assessments of various approaches to collecting and analyzing the results of serologic testing; and,
  • Incorporate the results of these public health activities into operational disease detection, prevention, and response or control programs in regions noted above, strengthen public health capacity as outlined in the Global Health Security Agenda, and disseminate findings across the region, with partners, and globally.
https://www.grants.gov/web/grants/view-opportunity.html?oppId=329700
Deadline: January 20, 2021 (LOI) and February 22, 2021 (Full Proposal)

US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
The goal of this Notice of Funding Opportunity (NOFO) is to support a network of US institutions to develop and implement standard research protocols to conduct prospective active surveillance for: a) acute gastroenteritis (AGE) due to norovirus, rotavirus and other enteric viruses; b) acute respiratory illnesses (ARI) due to respiratory viruses including, but not limited to, influenza, RSV, parainfluenza viruses, human metapneumovirus, rhinoviruses, enteroviruses (including EV-D68), adenoviruses, and coronaviruses (including SARS-CoV-2); and c) acute flaccid myelitis (AFM) syndrome and multisystem inflammatory syndrome in children (MIS-C) among pediatric patients seeking healthcare at medical institutions. The network should also provide accurate estimates of the effectiveness in this population of influenza, rotavirus, COVID-19 and other vaccines against respiratory or enteric virus-associated illnesses projected to become available during the period of performance (e.g., RSV, norovirus). Participating institutions should identify AGE, ARI, AFM and MIS-C illnesses among pediatric patients seeking healthcare or diagnostic testing for acute illness in inpatient, outpatient and emergency departments. Recipients should enroll patients meeting standard symptom criteria, and confirm viral infection using approved molecular assays. Vaccine effectiveness (VE) estimates will be calculated. Estimates of VE, burden of disease, and information on the natural history of disease will be used to: a) inform best practices for diagnosis and treatment protocols; b) inform vaccine recommendations; and c) assess public health impact of vaccination and public health programs to prevent viral illness-related healthcare encounters and medical visits among pediatric populations.
https://www.grants.gov/web/grants/view-opportunity.html?oppId=328354
Deadline: January 7, 2021 (LOI) and February 8, 2021 (Full Proposal)

Collaborative Research on Influenza, Coronavirus Disease 2019 (COVID-19), and Other Respiratory Pathogens in South Africa

The purpose of this Notice of Funding Opportunity (NOFO) is to conduct research studies on influenza, coronavirus disease 2019 (COVID-19), and other respiratory pathogens in South Africa. The National Center for Immunization and Respiratory Diseases (NCIRD) and the Center for Global Heath (CGH) are seeking to initiate a cooperative agreement with the National Institute for Communicable Diseases (NICD), Republic of South Africa, to conduct studies on the epidemiology, disease burden, transmission, risk factors for hospitalization and death from respiratory viral diseases, especially influenza and COVID-19. Data will be used to inform prioritization of public health interventions in high risk populations in South Africa.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=330625

Deadline: March 9, 2021

Private Foundations, Corporations and Other Agencies


Cisco Research Center (CRC) Pandemic/COVID19 Science, Technology and Social Impact
Pandemics have far reaching consequences that range from deaths to shutting down the economy as we have witnessed during the recent COVID19 crisis. Hence there is a need to be better prepared for such pandemics. We need to solve problems ranging from predictive analytics innovative devices for saving lives to technology for devising voting machines. The social and economic impact for the above areas is huge and some of the work can be transformative and save lives.  Areas of interest to us include, but are not limited to:  Mathematical models for spread and the impact of pandemics; Scalable simulation techniques for pandemics (e.g. with multi agents); Biomedical/Nano sensor devices for detecting symptoms and agents; Algorithms for rapid exploration of the drug screening and discovery workflows (e.g. use reinforcement learning); Advanced computational biology techniques for sequencing, detecting viral evolution (e.g. in COVID-19); Algorithms and systems for contact tracing (with privacy preserving).; Algorithms and recommendation systems for curating media and news; Collaboration techniques for more effective health, and efficiency during pandemics; Improved identity and security techniques; Distributed Ledgers, their applications and their governance for and during pandemics; Pandemic data science - understanding the patterns and the impact of a pandemic like COVID-10; and Creation of curated data sets.  We are interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them. By cultivating stronger partnerships between scientists, technologists, and the broader community; we hope to achieve an acceleration of scientific research and conservation outcomes as we push the boundaries of our technologies and architectures to support larger-scale studies, more sophisticated analyses, and translation of learnings across multiple domain areas.
Deadline: Applications will be accepted on a rolling basis

Coronavirus Urgent Response Initiative  
The Draper Richards Kaplan Foundation invites applications for funding under its COVID-19 urgent response initiative. This supports innovative solutions that address time-critical social problems caused by the COVID-19pandemic. Solutions should be fully scalable, lead to lasting change and be deployable within 30 days.

COVID-19 Collective Fund for Trans Communities
Borealis Philanthropy's Fund for Trans Generations, Destination Tomorrow's TRANScend Community Impact Fund, and Third Wave Fund have launched the COVID-19 Collective Fund for Trans Communities to get financial resourcesto trans-led organizations and transgender, gender nonconforming, and non-binary communities who are organizing in response to the COVID-19 crisis. Priority will be given to trans-led organizations with a racial justice focus. We encourage requests by Black, Indigenous, and other people of color (BIPOC). Some examples of activities that may be supported by this collective's grantmaking include, but are not limited to: Mutual aid and care support networks; Healing and virtual wellness spaces; Online/virtual programming needs; Living stipends for members and/or staff; Survival needs i.e. food, rent support, shelter, utilities; and Organizing and advocacy. 
https://borealisphilanthropy.org/grantmaking/fund-for-trans-generations/covid-19-collective-fund-for-trans-communities/
Deadline: rolling

Direct COVID-19 Response - Charitable Grant  
The effect of the COVID-19 pandemic on the impact sector has reached natural disaster proportions in its scope and scale, which means that the global need for our 'emergency' capital vastly outstrips our available resources. Given this reality, we have decided to use our limited resources to best serve the sector under the following circumstances: Charitable Grants will only be offered to organizations responding directly to COVID-19. This grant is for organizations engaging in direct COVID-19 response. We will prioritize organizations and activities that have a clear and direct role in `flattening the curve' and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Slowing and stopping the spread of COVID-19 is directly linked to reducing and limiting the economic and social hardship our communities are experiencing.
https://openroadalliance.org/covid-19/
Deadline: rolling

Mozilla COVID-19 Solutions Fund 
The Mozilla Open Source Support (MOSS) Program, created in 2015, broadens access, increases security, and empowers users by providing catalytic funding to open source technologists. We have already seen inspiring examples of open source technology being used to increase the capacity of the world's healthcare systems to cope with this crisis. As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation)
Deadline: rolling             

Novartis US COVID-19 Community Response Fund
In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. Programs must support one or more of the three stated objectives: (1) strengthening local and national healthcare infrastructure to meet increased demand and protect frontline health workers, (2) establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information, and (3) creating or enhancing new community health programs specific to the pandemic response.
https://www.novartis.us/news/novartis-us-covid-19-initiatives
Deadline: rolling

Williams Foundation  
The  Williams Foundation has pledged $1 million to make grants to community organizations that focus primarily on emergency response, food insecurity, health and human services, and distance-learning solutions for public schools throughout the coronavirus outbreak. Eligible recipients include nonprofit groups, first responders, and public schools in the 24 states where the natural-gas company does business.
https://investor.williams.com/press-releases/press-release-details/2020/Williams-Foundation-Pledges-1-Million-for-Coronavirus-Response-and-Community-Recovery/default.aspx
Deadline: rolling

Hayek Fund for Scholars
The Hayek Fund for Scholars supports students and faculty who are researching and teaching the ideas of liberty within the social sciences and humanities by funding a wide range of research- and career-advancing activities. From paying for PhD application fees to conference presentation travel to the purchase of crucial data sets, this unique fund helps cover an extensive array of expenses. The Hayek Fund helps pay for activities including (but not limited to):

  • Expenses related to remote/online teaching and scholarly collaboration incurred as a consequence of the COVID-19 pandemic
  • Purchase of books or online resources to support teaching and research
  • Travel for paper presentations or job interviews at academic conferences
  • Submission fees for unpublished manuscripts and academic journal articles
  • Travel for archival research*
  • Purchase of data sets
  • Participation in seminars or peer reviews*
  • Collaborative research projects or the hiring of a research assistant
  • Facilitation of thought-provoking reading groups and book clubs with students*
  • Reimbursement of application fees for PhD programs
*Note restrictions.
https://theihs.org/funding/hayekfund/
Deadline: rolling

Amazon Web Services Diagnostic Development Initiative (DDI)
The AWS Diagnostic Development Initiative (DDI) provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks. Although vaccine and treatment development research is generally funded by private foundations and government agencies, fast and reliable diagnostic techniques are slow to be developed. Accurate testing and diagnosis at point-of-care or regional locations for patients with COVID-19 is critical to early intervention and treatment. AWS is offering technical support and providing AWS promotional credits to support the use of AWS services to advance diagnostic research for selected institutions and companies.
https://aws.amazon.com/government-education/nonprofits/disaster-response/diagnostic-dev-initiative/
Deadline: rolling

Wellcome Trust - The COVID-19 Therapeutics Accelerator
Wellcome joins the Bill & Melinda Gates Foundation and Mastercard in launching a new initiative to speed the development of and access to therapies for COVID-19. The COVID-19 Therapeutics Accelerator will coordinate research efforts and remove barriers to drug development. Currently there are no approved treatments for COVID-19. This new initiative aims to fill that gap by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The partners are committed to equal access, ensuring treatments are accessible and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator will work closely with the World Health Organization, government and private sector funders, and global regulatory and policy-setting institutions. It will have an end-to-end focus - from drug pipeline development through to manufacturing and scale-up - and will provide fast and flexible funding at key stages of the process.
https://wellcome.ac.uk/news/wellcome-pledges-50-million-new-initiative-speed-development-covid-19-treatments
Deadline: rolling

Equal Sound Corona Relief Fund
The Equal Sound Corona Relief Fund was set up on short notice to provide direct financial assistance to musicians who have lost work as a result of Corona-related event cancellations.
https://equalsound.org/project/corona-relief-fund/
Deadline: rolling

Robert Wood Johnson Foundation Pioneering Ideas: Exploring the Future to Build a Culture of Health
Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. We are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. We want to hear from scientists, anthropologists, artists, urban planners, community leaders—anyone, anywhere who has a new or unconventional idea that could alter the trajectory of health, and improve health equity and well-being for generations to come. The changes we seek require diverse perspectives and cannot be accomplished by any one person, organization or sector. While this call for proposals is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, we recognize the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.
Deadline: Proposals will be accepted throughout the year on a rolling admission

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Dissemination and Implementation Awards
PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis with enhancements to currently funded PCORI Dissemination and Implementation awards. Only PCORI-funded investigators or project leads with active Dissemination and Implementation Award contracts are eligible to submit a proposal in response to this announcement. PCORI has a strong interest in addressing dilemmas facing patients, clinicians, health systems, and other stakeholders and entities battling the novel coronavirus pandemic in the United States. We are interested in supporting work that can be initiated quickly to mitigate the outcome of the current pandemic by using existing teams with ongoing working relationships with PCORI. Taking advantage of natural experiments in health system, state, and provider responses is encouraged. Proposed enhancements should boost the existing Dissemination and Implementation project’s overall impact and do so by responding to needs evolving or emerging in the context of the COVID-19 pandemic. Such needs include, but are not limited to, challenges to mental health and well-being of healthcare workers, social support for vulnerable populations experiencing isolation or restrictions in mobility, prevention and treatment of COVID-19, and health system adaptations to compensate for shortages of personnel and supplies.
https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-dissemination-implementation-awards
Deadline: rolling

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards  
PCORI has a strong interest in generating timely findings to provide answers to dilemmas facing patients, clinicians, health systems, and other stakeholders and entities battling the novel coronavirus pandemic in the United States. Through this announcement, we are interested in supporting Enhancements to existing Engagement Awards that can be initiated sufficiently quickly to influence the outcome of the current pandemic by using existing teams that are currently funded by PCORI. They should have some relationship to the original award. Enhancements may include modest additions to existing aims, or an adjunct project that has some relationship to the original award, including a new aim (or aims) designed to produce useful knowledge or research support related to COVID-19 and the original award. Simultaneous adaptation of original aims to account for COVID-19 may also be proposed. Taking advantage of natural experiments in health system, state, and provider responses is encouraged.  Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement. 
https://www.pcori.org/funding-opportunities/announcement/covid-19-related-enhancements-engagement-awards 
Deadline: rolling 

Arts Administrators of Color: Arts Leaders of Color Emergency Fund
Arts Administrators of Color has created the Arts Leaders of Color Emergency Fund, which supports BIPOC (Black, Indigenous, and People of Color) artists and arts administrators impacted by COVID-19 through one-time microgrants of $200.
https://aacnetwork.org/
Deadline: rolling

Merck KGaA Research Grant for Pandemic Preparedness
Research grants for technological solutions towards pandemic outbreak preparedness or solutions that could help fighting emerging viral infections. Proposals will be considered that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections. Pre-outbreak R&D Preparedness for pandemic disease: Assessing the priority of pathogens and diseases with epidemic threat; Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats; and Innovative technologies for better personal protection equipment for infection control. Response during outbreak: Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation; and Fast-track identifying, testing and production of effective drugs and vaccines during outbreak.
https://www.emdgroup.com/en/research/open-innovation/2020-research-grants/research-grant-pandemic-preparedness.html.html
Deadline: rolling

Fast Funding for COVID-19 Science 

Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this. If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 14 days. If we approve the grant, you'll receive payment as quickly as your university can receive it. You must be: A PI at an academic institution; Already working on a project that could help with the COVID-19 pandemic within the next six months; and In need of additional funding to complete the project.
https://fastgrants.org/ 

Deadline: Applications are accepted until funds run out.

Direct COVID-19 Response – Charitable Grant

Open Road makes one-time grants for discrete solutions that help projects overcome unexpected roadblocks. We have no sector or geographic focus, but rather all situations must meet the following four criteria to be eligible for an investment: Mid-Implementation: If not for this roadblock your organization wouldn’t need funding – all of the necessary operating funds for the year/period/grant were secured, and then something unexpected occurred necessitating additional funding; Unexpected: The roadblock experienced must be unexpected – it cannot be the result of an internal error or pivot but rather something external to the organization; Discrete: The solution to your roadblock must be discrete, requiring a one-time infusion of funds that is not recurring, and does not “kick the can down the road.” We want to fully solve the problem at hand; and Catalytic: The organization’s impact model must have the potential to be system-changing, either in design or scale, creating an amplifier or multiplier effect.

https://openroadalliance.org/resource/covid-19/

Deadline: Applications are accepted on a rolling basis

Stop the Spread COVID Response Program

Stop the Spread’s COVID Response Program is keenly focused on working with companies and organizations—large and small—to spur development of PPE for both medical and non-medical use, novel testing solutions, widely-accessible therapeutics and digital health solutions to address the needs of underserved communities and vulnerable populations.Topics include testing, vaccines, hyperlocal support, health services, PPE, therapeutics, and ventilators.

https://www.stopthespread.org/

Deadline:  Inquiries are accepted on a rolling basis

Dart Awards for Excellence in Coverage of Trauma

The Dart Awards for Excellence in Coverage of Trauma recognize exemplary journalism about the impact of violence, crime, disaster and other traumatic events on individuals, families and communities. Entries should focus on the experience of victims and survivors as well as contribute to public understanding of trauma. The Dart Awards honor North American newspaper, magazine, online, audio, television, video and multimedia journalism that goes beyond the ordinary in reporting on trauma. They are team prizes, reflecting the range of contributors and elements that shape the entry. Past winners include some of the world’s best-known news organizations as well as small local and community outlets.  In addition to the traditional Dart Awards for Excellence in Coverage of Trauma, this year we will be giving a special Dart Award for Outstanding Coverage of the Covid-19 Crisis in recognition of the exceptional challenges posed by the pandemic across the journalism community.

https://dartcenter.org/programs/awards

Deadline: January 27, 2021

Additional Resources and Databases

SDSN’s Epidemiology and Economics of Coronavirus Webinar
The Sustainable Development Solutions Network hosted a webinar to examine the implications of COVID-19 for public health and the SDGs, as well as to make recommendations on science-based responses. A recording of the video will be available on the SDSN YouTube channel.
https://www.unsdsn.org/e-conference-the-epidemiology-and-economics-of-coronavirus

NIH/NCBI/NLM’s LitCovid Literature Hub
LitCovid is a curated literature hub for tracking up-to-date scientific information about the Coronavirus. It is the most comprehensive resource on the subject, providing central access to a growing number of relevant articles in PubMed. The articles are updated daily and are further categorized by different research topics and geographic locations for improved access.
https://www.ncbi.nlm.nih.gov/research/coronavirus/